GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
Single comment threadYou are looking at one branch of small win: SURMOUNT stopped being a problem at week 65 — 52 comments in the full submission. View in context.
1.8k
c/trialwatch·submitted 5 months ago by u/joaquin_stanescu

small win: SURMOUNT stopped being a problem at week 65

Trial Databranch of 9 comments

Right, the SURMOUNT question again, but with numbers this time. I have 5 data points over 6 weeks. The pattern is consistent enough that I do not think it is chance, and boring enough that nobody is going to screenshot it, which is usually a good sign. The thing I would flag for anyone new: the effect I am describing…

Read the full submission and all 52 comments →

This branch

9 comments, started 5 months ago
u/formulary_fighterappeals27 points·5 months ago

the 18 week readout is different from the 6 week readout

replysharereportpermalink
u/yusuf_achebe18 points·5 months ago

phase 2 is not phase 3, smaller n and shorter trial

replysharereportpermalink
u/hedda_adeyemi5 points·5 months ago·edited

phase 2 is not phase 3, smaller n and shorter trial

Disagree on that part. 99.0% and 98.9% on the same vial is normal.

replysharereportpermalink
u/nora_oyelaran0 points·5 months ago

STEP, SURMOUNT, SURPASS, SELECT, FLOW, TRIUMPH — read the appendix

replysharereportpermalink
u/week_one_wanda12 points·5 months ago

I am going to push back on this slightly.

replysharereportpermalink
u/joaquin_stanescu32 points·5 months ago

You have restated the marketing copy. What is the actual substance here.

replysharereportpermalink
u/arne_ilunga37 points·5 months ago

off-label use data is different from approved-indication data

replysharereportpermalink
u/forest_plot_fionastats17 points·5 months ago

press release SURPASS posts must be flaired until a publication exists

replysharereportpermalink
u/adaeze_weiss13 points·5 months ago

press release hazard ratio posts must be flaired until a publication exists

replysharereportpermalink

← back to the whole thread

About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Janoshik Analytical

Independent HPLC and mass spec. The number you get is the number they found.

janoshik.comSponsored

GL Biochem (Shanghai)

Custom peptides and amino acids direct from the manufacturer since 1998. ISO 9001 / cGMP. Batch COA every order.

glbiochem.net
More in c/trialwatch
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Full rules and how they are enforced →
Moderators
u/trialwatch_theou/forest_plot_fionau/hazard_ratio_halu/renal_outcomes_r
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.

Full disclaimer →